GNPXMEDIUM SIGNALFINANCIAL10-K

GNPX significantly improved its financial position with a nearly 5x increase in cash and stockholders' equity while reducing operating losses by 27%.

The company appears to have completed a successful capital raise, dramatically strengthening its balance sheet with cash increasing from $1.6M to $7.8M and equity rising nearly 400%. The simultaneous reduction in operating losses suggests improved operational efficiency, though the company remains unprofitable and cash-burn dependent as a clinical-stage biotech.

Comparing 2026-03-30 vs 2025-04-01View on EDGAR →
FINANCIAL ANALYSIS

GNPX experienced a transformative financial period with cash and stockholders' equity both increasing nearly 400%, indicating a successful capital raise that strengthened the balance sheet considerably. Operating losses improved meaningfully from -$21.2M to -$15.5M, while operating cash flow also improved from -$17.1M to -$15.3M, suggesting better expense management. The overall picture signals a company that has secured near-term funding stability while demonstrating improved operational discipline, though it remains in the cash-burning phase typical of clinical-stage biotechnology companies.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+1909.6%
$2K→$38K

Interest expense surged 1909.6% — significant debt increase or rising rates materially impacting earnings.

Stockholders Equity
Balance Sheet
+391.4%
$1.6M→$8.0M

Equity base grew 391.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Cash & Equivalents
Balance Sheet
+388.9%
$1.6M→$7.8M

Cash position surged 388.9% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+302.3%
$2.1M→$8.4M

Current assets grew 302.3% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+146.3%
$4.1M→$10.2M

Asset base grew 146.3% — expansion through organic growth, acquisitions, or capital deployment.

Operating Income
P&L
+26.7%
-$21.2M→-$15.5M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+23.1%
-$21.1M→-$16.2M

Net income grew 23.1% — bottom-line growth signals improving overall business health.

Current Liabilities
Balance Sheet
-13.2%
$2.5M→$2.2M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-12.3%
$2.5M→$2.2M

Liabilities reduced 12.3% — deleveraging improves balance sheet strength and financial flexibility.

Operating Cash Flow
Cash Flow
+10.7%
-$17.1M→-$15.3M

Operating cash flow grew 10.7% — strong conversion of earnings to cash, healthy business fundamentals.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-04-01
ADDED
false --12-31 FY 2025 true true true false Our board of directors is responsible for the oversight of cybersecurity risk management.
The board of directors delegates oversight of the cybersecurity risk management program to the audit committee of the board of directors (the Audit Committee ).
The Audit Committee updates the board of directors on our cybersecurity risk management program, including any critical cybersecurity risks, ongoing cybersecurity initiatives and strategies, and applicable regulatory requirements and industry standards on an annual and as-needed basis.
Our board of directors is responsible for the oversight of cybersecurity risk management.
The board of directors delegates oversight of the cybersecurity risk management program to the audit committee of the board of directors (the Audit Committee ).
+7 more — sign up free →
REMOVED
false --12-31 FY 2024 false true true true false false false false 0.001 0.001 10,000,000 10,000,000 0 0 0 0 0.001 0.001 200,000,000 200,000,000 10,860,655 10,860,655 1,485,902 1,485,902 3 5 0 0 5 5 5 0 10.05 37.99 9.85 37.10 5 5 5 10 0 121.11 123.19 121.67 121.11 123.41 124.73 3 1 Inclusive of $3.3 million and $5.4 million of stock-based compensation expense for the years ended December 31, 2024 and 2023, respectively, and $6,693 and $15,004 of depreciation and amortization expense for the years ended December 31, 2024 and 2023, respectively.
As of March 28, 2025, there were 24,152,848 shares of the registrant s common stock outstanding.
For example, statements concerning financial condition, possible or assumed future results of operations, growth opportunities, industry ranking, plans and objectives of management, markets for our common stock and future management and organizational structure and statements about our current or future product candidates and their development, our beliefs regarding their preclinical or clinical profile or efficacy, and the regulatory approval process and pathway and the timing thereof, are all forward-looking statements.
MD Anderson is currently analyzing biomarkers that would indicate lack of response in lung cancer that could enrich our population of responders in our clinical trials and enhance patient screening and enrollment in order to increase the likelihood of potential success of the Acclaim studies for the Company.
Based on a review of safety data which showed no dose limiting toxicities ( DLTs ), the Acclaim-1 SRC determined the recommended Phase 2 dose ( RP2D ) of REQORSA to be 0.12 mg/kg.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →